Get the Stockscreener App
9.48
0.42%
0.04
After Hours:
9.48
Artiva Biotherapeutics Inc stock is traded at $9.48, with a volume of 312.62K.
It is up +0.42% in the last 24 hours and up +38.39% over the past month.
Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).
See More
Previous Close:
$9.44
Open:
$9.44
24h Volume:
312.62K
Relative Volume:
0.54
Market Cap:
$460.62M
Revenue:
$251.00K
Net Income/Loss:
$-87.07M
P/E Ratio:
-2.6709
EPS:
-3.5494
Net Cash Flow:
$-80.18M
1W Performance:
-2.27%
1M Performance:
+38.39%
6M Performance:
+106.09%
1Y Performance:
+500.00%
1-Day Range:
$9.11
$10.00
1-Week Range:
$9.11
$10.24
52-Week Range:
$1.59
$14.53
Artiva Biotherapeutics Inc Stock (ARTV) Company Profile
Name
Artiva Biotherapeutics Inc
Sector
Industry
Phone
(858) 267-4467
Address
5505 MOREHOUSE DRIVE, SAN DIEGO
Compare ARTV vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARTV
Artiva Biotherapeutics Inc
|
9.48 | 458.67M | 251.00K | -87.07M | -80.18M | -3.5494 |
VRTX
Vertex Pharmaceuticals Inc
|
522.25 | 134.41B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
676.23 | 68.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.93 | 57.01B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
321.50 | 41.79B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
190.46 | 40.39B | 742.00K | -1.37B | -1.07B | -7.0731 |
Artiva Biotherapeutics Inc Stock (ARTV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-11-25 | Resumed | H.C. Wainwright | Buy |
| Dec-30-24 | Initiated | H.C. Wainwright | Buy |
| Aug-13-24 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-13-24 | Initiated | Jefferies | Buy |
| Aug-13-24 | Initiated | Needham | Buy |
| Aug-13-24 | Initiated | TD Cowen | Buy |
| Aug-13-24 | Initiated | Wedbush | Outperform |
View All
Artiva Biotherapeutics Inc Stock (ARTV) Latest News
Artiva Biotherapeutics at H.C. Wainwright: allogeneic cell therapy push By Investing.com - Investing.com Canada
Major Stake Boost Signals Growing Confidence in Artiva Biotherapeutics - TipRanks
Ra capital funds buy $292k Artiva Biotherapeutics stock in late June - Investing.com South Africa
Artiva Biotherapeutics, Inc.(NasdaqGM: ARTV) added to Russell 2000 Index - marketscreener.com
Form 4 Artiva Biotherapeutics Inc For: 29 June By Investing.com - Investing.com South Africa
Artiva Biotherapeutics, Inc.(NasdaqGM: ARTV) added to Russell 2500 Growth Benchmark - marketscreener.com
Artiva Biotherapeutics, Inc.(NasdaqGM: ARTV) added to Russell 2000 Value Benchmark - marketscreener.com
Artiva Biotherapeutics, Inc.(NasdaqGM:ARTV) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Artiva Biotherapeutics, Inc.(NasdaqGM: ARTV) added to Russell 2000 Growth Benchmark - marketscreener.com
Artiva Biotherapeutics, Inc.(NasdaqGM: ARTV) added to Russell 3000E Growth Benchmark - marketscreener.com
Artiva Biotherapeutics, Inc.(NasdaqGM: ARTV) added to Russell 2000 Dynamic Index - marketscreener.com
Price to sales forward of Artiva Biotherapeutics, Inc. – NASDAQ:ARTV - TradingView
Price to book forward of Artiva Biotherapeutics, Inc. – NASDAQ:ARTV - TradingView
Enterprise value to revenue forward of Artiva Biotherapeutics, Inc. – NASDAQ:ARTV - TradingView
Enterprise value to EBITDA forward of Artiva Biotherapeutics, Inc. – NASDAQ:ARTV - TradingView
Price to earnings forward of Artiva Biotherapeutics, Inc. – NASDAQ:ARTV - TradingView
Artiva Biotherapeutics, Inc. advances AlloNK therapy toward Phase 3 in autoimmune disease - Traders Union
Artiva Biotherapeutics Inc (ARTV) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Artiva Biotherapeutics, Inc. Actuals & Estimates (NASDAQ:ARTV) - TradingView
ARTV Forecast — Price Target — Prediction for 2027 - TradingView
Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference - GlobeNewswire
Artiva Biotherapeutics Inc (ARTV) Institutional Confidence - TradingKey
RA CAPITAL MANAGEMENT, L.P. Increases Stake in Artiva Biotherape - GuruFocus
ARTV News | ARTIVA BIOTHERAPEUTICS INC (NASDAQ:ARTV) - ChartMill
Artiva Biotherapeutics Inc (ARTV) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Artiva Biotherapeutics Inc (ARTV) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Artiva Biotherapeutics Inc (ARTV) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Artiva Biotherapeutics Inc (ARTV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Artiva Biotherapeutics Inc (ARTV) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Artiva Biotherapeutics Inc (ARTV) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Artiva Biotherapeutics Inc (ARTV) Valuation: PE, PB & Fair Value Analysis - TradingKey
Tuesday’s insider activity: Major buys in energy and biotech By Investing.com - Investing.com India
Tuesday’s insider activity: Major buys in energy and biotech - Investing.com
Artiva Biotherapeutics(ARTV.US) 10% Shareholder Buys US$4.6 Million in Common Stock - Moomoo
Major Insider Makes Bold New Bet on Artiva Biotherapeutics Stock - TipRanks
Ra capital acquires $4.6m in Artiva Biotherapeutics shares By Investing.com - Investing.com India
Ra capital acquires $4.6m in Artiva Biotherapeutics shares - Investing.com UK
Artiva: Targeting A New Benchmark In Refractory Rheumatoid Arthritis With AlloNK - RTTNews
Thursday’s insider buys and sells: Healthcare and tech in focus - Investing.com UK
Thursday’s insider buys and sells: Healthcare and tech in focus By Investing.com - Investing.com India
Major Insider Move Signals Growing Confidence in Artiva Biotherapeutics - TipRanks
Ra capital funds acquire $7.65m in Artiva Biotherapeutics stock By Investing.com - Investing.com Nigeria
Ra capital funds acquire $7.65m in Artiva Biotherapeutics stock - Investing.com UK
ARTV Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Advances PipelineEarnings Weakness Phase - newsline.com
ARTV Q1 2026 Earnings: Surprise EPS Miss Amid Pre-Revenue Stage, Stock Gains 6.91%Net Income Trends - lwvtexas.org
Artiva Biotherapeutics Inc Stock (ARTV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Artiva Biotherapeutics Inc Stock (ARTV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Director |
Jun 26 '26 |
Buy |
8.98 |
1,876 |
16,846 |
16,795,919 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Jun 12 '26 |
Buy |
8.57 |
391,019 |
3,351,033 |
16,622,736 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Jun 16 '26 |
Buy |
8.89 |
124,893 |
1,110,299 |
16,763,043 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Jun 15 '26 |
Buy |
8.99 |
15,414 |
138,572 |
16,638,150 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Jun 11 '26 |
Buy |
7.91 |
548,580 |
4,339,268 |
16,231,717 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Jun 09 '26 |
Buy |
6.91 |
479,039 |
3,310,159 |
15,683,034 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Jun 10 '26 |
Buy |
7.00 |
103 |
721 |
15,683,137 |
| GC Corp. | 10% Owner |
May 11 '26 |
Buy |
11.52 |
1,085,069 |
12,499,995 |
4,391,969 |
| GC Corp. | 10% Owner |
May 11 '26 |
Buy |
11.52 |
347,222 |
3,999,997 |
1,607,734 |
| Raymon Heather | SVP, Research and Development |
May 19 '26 |
Sale |
9.01 |
3,095 |
27,879 |
148,228 |
1.18%
2.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):